Drug intelligence / Profile preview

AX-LAH3 MAb

Development stage: Discontinued
Lead developer: iQur
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

AX-LAH3 MAb is a monoclonal antibody developed by iQur using its virus-like particle (VLP) platform technology. It is designed to target the long alpha helix 3 (LAH3) region of the HA2 subunit within the stalk domain of the H3 hemagglutinin of Influenza A virus. AX-LAH3 MAb acts as a universal antibody that recognizes all strains within the H3 subtype variants. Rather than being developed as a clinical therapeutic, the antibody has been made available as a research tool and diagnostic reagent through the NIH-associated BEI Resources repository (catalog number NR-50513) managed by ATCC.

Other names: AX-LAH3 MAbAX-LAH-3 MAbAX-LAH 3 MAbNR-50513NR50513NR 50513

Targets

H3 HA (Influenza A hemagglutinin H3)

Beyond the preview

Go deeper on AX-LAH3 MAb.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AX-LAH3 MAb.

Explore the full profile